Nebenwirkungen · Olazax Disperzi
Olazax Disperzi 10 mg orodispersible tablets · Abschnitt 4.8 · PDF-Seite 28
HOS-211617 · Präparat HOS-154713
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %). With long-term exposure (at least 24 weeks), 89.4 % gained ≥ 7 %, 55.3 % gained ≥ 15 % and 29.1 % gained ≥ 25% of their baseline body weight. 14 Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (≥ 1.467 mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to high (≥ 1.467 mmol/l). 15 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/l) to high (≥ 5.17 mmol/l) were observed commonly. Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39 - < 5.17 mmol/l) to high (≥ 5.17 mmol/l) were very common. 16 Elevated plasma prolactin levels were reported in 47.4 % of adolescent patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-12T12:00:00Z · SHA-256 9bf3c3e03daaaca2910b9d1ea3d0e6aa19e623a526c95d8cb3f4655bbe93b9dd · Passage 88c2e4afe1d6ed70329fbf18adae3fd989f763947c757467e38db8308a0f81a6 · Zeichen 14547–15504 im Abschnitt